Myelodysplastic syndrome

Fusion driven JMML: a novel CCDC88C–FLT3 fusion responsive to sorafenib identified by RNA sequencing

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1
Fig. 2

References

  1. 1.

    Stieglitz E, Ward AF, Gerbing RB, Alonzo TA, Arceci RJ, Liu YL, et al. Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: a report from the Children’s Oncology Group. Pediatr blood cancer. 2015;62:629–36.

    CAS  Article  Google Scholar 

  2. 2.

    Dvorak CC, Satwani P, Stieglitz E, Cairo MS, Dang H, Pei Q, et al. Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: sa Children’s Oncology Group study. Pediatr blood cancer. 2018;65:e27034.

    Article  Google Scholar 

  3. 3.

    Stieglitz E, Taylor-Weiner AN, Chang TY, Gelston LC, Wang YD, Mazor T, et al. The genomic landscape of juvenile myelomonocytic leukemia. Nat Genet. 2015;47:1326–33.

    CAS  Article  Google Scholar 

  4. 4.

    Stieglitz E, Troup CB, Gelston LC, Haliburton J, Chow ED, Yu KB, et al. Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia. Blood. 2015;125:516–24.

    CAS  Article  Google Scholar 

  5. 5.

    Locatelli F, Nollke P, Zecca M, Korthof E, Lanino E, Peters C, et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. Blood. 2005;105:410–9.

    CAS  Article  Google Scholar 

  6. 6.

    Murakami N, Okuno Y, Yoshida K, Shiraishi Y, Nagae G, Suzuki K, et al. Integrated molecular profiling of juvenile myelomonocytic leukemia. Blood. 2018;131:1576–86.

    CAS  Article  Google Scholar 

  7. 7.

    Baldwin BR, Li L, Tse KF, Small S, Collector M, Whartenby KA, et al. Transgenic mice expressing Tel-FLT3, a constitutively activated form of FLT3, develop myeloproliferative disease. Leukemia. 2007;21:764–71.

    CAS  Article  Google Scholar 

  8. 8.

    Falchi L, Mehrotra M, Newberry KJ, Lyle LM, Lu G, Patel KP, et al. ETV6-FLT3 fusion gene-positive, eosinophilia-associated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem cell transplant. Leukemia. 2014;28:2090–2.

    CAS  Article  Google Scholar 

  9. 9.

    Stirewalt DL, Kopecky KJ, Meshinchi S, Engel JH, Pogosova-Agadjanyan EL, Linsley J, et al. Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia. Blood. 2006;107:3724–6.

    CAS  Article  Google Scholar 

  10. 10.

    Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98:1752–9.

    CAS  Article  Google Scholar 

  11. 11.

    Bown N, Y SM, Evans J, Kernahan J, Reid MM. Chronic myelomonocytic leukemia with t(13;14) in a child. Cancer Genet Cytogenet. 1992;60:190–2. 1992

    CAS  Article  Google Scholar 

  12. 12.

    Buijs A, Bruin M. Fusion of FIP1L1 and RARA as a result of a novel t(4;17)(q12; q21) in a case of juvenile myelomonocytic leukemia. Leukemia. 2007;21:1104–8.

    CAS  Article  Google Scholar 

  13. 13.

    Morerio CA M, Rosanda C, Rapella A, Dufour C, Locatelli F, Maserati E, et al. HCMOGT-1 is a novel fusion partner to PDGFRB in juvenile myelomonocytic leukemia with t(5;17)(q33; p11.2). Cancer Res. 2014;64:2649–51.

    Article  Google Scholar 

  14. 14.

    Byrgazov K, Kastner R, Dworzak M, Hoermann G, Haas OA, Ulreich R, et al. A novel fusion gene NDEL1-Pdgfrb in a patient with JMML with a new variant of TKI-resistant mutation in the kinase domain of PDGFR beta. Blood. 2014;124:613.

    Article  Google Scholar 

  15. 15.

    Mizoguchi Y, Fujita N, Taki T, Hayashi Y, Hamamoto K. Juvenile myelomonocytic leukemia with t(7;11)(p15; p15) and NUP98-HOXA11 fusion. Am J Hematol. 2009;84:295–7.

    Article  Google Scholar 

Download references

Acknowledgements

We thank the family for their willingness to share their story. This work was supported by the National Institutes of Health, National Cancer Institute grant 1U54CA196519 (M.L.L., E.S.); National Institutes of Health, National Heart, Lung, and Blood Institute grant K08HL135434 (E.S.); Alex’s Lemonade Stand, Center of Excellence (M.L.L., E.S.) and the Frank A. Campini Foundation (M.L.L. and E.S.). C.S. is the Damon Runyon-Richard Lumsden Foundation Clinical Investigator supported (in part) by the Damon Runyon Cancer Research Foundation (CI-99-18).

Author information

Affiliations

Authors

Contributions

A.K.C. and J.A.M. performed the ddPCR and Ba/F3 experiments and analyzed the data; A.G.L. and J.V.Z. analyzed the data; A.K.K., B.S.B., E.A.S., C.C.S., C.C.D., T.T., A.H. all advised on design of the experiments; A.K.C. and E.S. wrote the manuscript; J.A.M., A.G.L., J.V.Z., A.K.K., C.G., B.S.B, E.A.S., C.C.S., C.C.D., M.L.L., T.T., A.H. edited the manuscript; E.S. supervised the experiments; and all authors reviewed the literature, contributed to specific sections, and reviewed the final version of the manuscript.

Corresponding author

Correspondence to Elliot Stieglitz.

Ethics declarations

Conflict of interest

C.S. received research funding from FujiFilm and Astellas Pharma. A.K.C. received an honoraria from Bio-Rad for speaking at a symposium. No other authors declare conflicts of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Chao, A.K., Meyer, J.A., Lee, A.G. et al. Fusion driven JMML: a novel CCDC88C–FLT3 fusion responsive to sorafenib identified by RNA sequencing. Leukemia 34, 662–666 (2020). https://doi.org/10.1038/s41375-019-0549-y

Download citation

Further reading

Search